Narrows 2025 revenue view to $3.15B-$3.2B from $3.125B-$3.2B, consensus $3.17B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin’s Vosoritide Study: A Potential Game-Changer for Hypochondroplasia Treatment
- BioMarin’s Vosoritide Study: A Potential Game-Changer in Pediatric Growth Disorders
- BioMarin’s Long-Term Study on BMN 270: A Potential Game Changer for Hemophilia A
- BioMarin’s Vosoritide Study: A Long-Term Hope for Hypochondroplasia
- BioMarin’s BMN 351 Study: A New Hope for Duchenne Muscular Dystrophy